Xenon Pharmaceuticals (XENE) Receivables (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 13 years of Receivables data on file, last reported at $15.8 million in Q1 2025.

• On a quarterly basis, Receivables rose 1800.0% year-over-year to $15.8 million in Q1 2025; TTM through Mar 2025 was $15.8 million, a 1800.0% increase from a year earlier, with the FY2024 full-year figure at $2.9 million, up 294.89% from the prior year.
• Receivables for Q1 2025 stood at $15.8 million, up from $2.0 million in the prior quarter.
• Over the last five years, Receivables for XENE reached as high as $15.8 million in Q1 2025 and fell as low as $805000.0 in Q3 2023.
• Historically, Receivables has averaged $2.9 million across 5 years, with a median of $2.2 million in 2023.
• Across the five-year window, Receivables slumped 67.57% in 2023 and surged 1800.0% in 2025, its largest moves.
• Year by year, Receivables stood at $2.8 million in 2021, then slumped by 64.34% to $986000.0 in 2022, then decreased by 11.36% to $874000.0 in 2023, then jumped by 130.66% to $2.0 million in 2024, then surged by 685.07% to $15.8 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $15.8 million in Q1 2025, $2.0 million in Q4 2024, and $1.0 million in Q3 2024.